New results from an early clinical trial have offered hope that a drug for pulmonary arterial hypertension may be effective in the care of sickle cell patients.
The drug may be able to help hypertension and end organ damage in these patients, researchers have reported in the Lancet Haematology.
The Phase 1-2 study, STERIO-SCD, found that the drug riociguat appears to be safe and shows signs of effectiveness in patients with sickle cell disease.
Researchers at the University of Maryland, USA, tested the drug after other drugs were found to have unacceptable side effects.
The randomised control trial involved 130 patients with mild hypertension or having protein in the urine – a marker for developing kidney disease.
There were no statistic...
20 hours ago
